VORSCHAU
Frühere Meldungen
PRESSETERMINE
AKTUELLES PRESSEFOTO
IR Nachrichten
02.10.2024 18:05
CA Immobilien Anlagen AG
02.10.2024 18:00
CA Immobilien Anlagen AG
02.10.2024 18:00
CA Immobilien Anlagen AG
EUROPA NACHRICHTEN
ADHOC
Mi, 02.10.2024 15:00
pta20241002023
Business news for the stock market
Medigene AG: Medigene will Present at ASGCT 2024 and Host R&D EventPlanegg/Martinsried (pta023/02.10.2024/15:00) - Medigene AG ( http://www.medigene.com ) (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, will present a poster at the American Society of Gene & Cell Therapy (ASGCT) to be held October 16-17, 2024 in Philadelphia, PA in the US. In addition, the Company will host an R&D Event on Medigene's optimal 3S (specific, sensitive, and safe) TCRs for TCR-guided precision immunotherapies on Thursday, October 10, 2024, at 4.30 pm CEST / 10:30 am ET.
ASGCT 2024
Details of the poster presentations are as follows:
Abstract and Title
: "Seamless Integration of a Universal Epitope into Recombinant TCRs for Tagging and Tracking of TCR-T Cells Expressing 3S TCRs."
The poster will showcase the Company's newly introduced technology, UniTope & TraCR, an innovative combination of universal TCR tagging and tracking. This system is designed to significantly enhance the precision and efficiency of T cell receptor identification and monitoring, offering remarkable capabilities for immunotherapy research and clinical applications. Invite to the Company's R&D event on October 10, 2024
Medigene will host an R&D Event on Thursday, October 10, 2024, at 4.30 p.m. CEST / 10:30 a.m. ET. A live Q&A session will follow the formal presentations and discussions.
Registration details:
Following the call, an archived webcast will also be accessible on the Investors & Media section of the Medigene website https://www.medigene.com/investors-media/reports-presentations --- end of press release --- About Medigene AG Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer. Its End-to-End Platform generates optimal 3S (sensitive, specific and safe) T cell receptors with unique and distinctive attributes that are utilized in multiple therapeutic modalities, such as T cell receptor engineered T cell (TCR-T) therapies, TCR-guided T cell engager therapies and TCR-natural killer cell therapies for both its in-house product pipeline and partnering. Medigene's lead TCR-T program MDG1015 is a potential best-in-class, TCR-T therapy to treat multiple solid tumor indications. The End-to-End Platform technologies enable armoring and enhancing of these T cells to overcome the immunosuppressive tumor microenvironment (TME) and ensure the T cell drug product composition maximizes safety, efficacy and durability of response. Medigene's MDG1015 received IND approval in Q3 2024 and is filing for CTA in Q4 2024.For more information, please visit https://medigene.com/ This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.
Medigene AG
In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
(Ende)
PRESSETEXT.TV
PORR rechnet mit anhaltender Baukonjunktur 30.10.2024 ETARGET
FOCUSTHEMA
SPECIALS
Werbung
middleAdvertising
|